ZA200805739B - Anti-myosin Va sirna and skin depigmentation - Google Patents

Anti-myosin Va sirna and skin depigmentation

Info

Publication number
ZA200805739B
ZA200805739B ZA200805739A ZA200805739A ZA200805739B ZA 200805739 B ZA200805739 B ZA 200805739B ZA 200805739 A ZA200805739 A ZA 200805739A ZA 200805739 A ZA200805739 A ZA 200805739A ZA 200805739 B ZA200805739 B ZA 200805739B
Authority
ZA
South Africa
Prior art keywords
sirna
myosin
sense rna
rna strand
skin depigmentation
Prior art date
Application number
ZA200805739A
Other languages
English (en)
Inventor
Schmitt-Milas Anne-Marie
Lambert Jo
Westbroek Wendy
Van Gele Mireille
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Publication of ZA200805739B publication Critical patent/ZA200805739B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200805739A 2005-12-12 2008-07-01 Anti-myosin Va sirna and skin depigmentation ZA200805739B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0512553A FR2894582B1 (fr) 2005-12-12 2005-12-12 Sirna anti myosine va et depigmentation de la peau

Publications (1)

Publication Number Publication Date
ZA200805739B true ZA200805739B (en) 2009-07-29

Family

ID=36617133

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805739A ZA200805739B (en) 2005-12-12 2008-07-01 Anti-myosin Va sirna and skin depigmentation

Country Status (23)

Country Link
US (1) US7999096B2 (de)
EP (2) EP1963507B1 (de)
JP (1) JP2009518022A (de)
KR (1) KR20080079298A (de)
CN (1) CN101326286A (de)
AT (1) ATE484585T1 (de)
AU (1) AU2006325359A1 (de)
BR (1) BRPI0619738A2 (de)
CA (1) CA2632837A1 (de)
DE (1) DE602006017586D1 (de)
DK (1) DK1963507T3 (de)
ES (1) ES2351996T3 (de)
FR (1) FR2894582B1 (de)
HR (1) HRP20100666T1 (de)
IL (1) IL191728A0 (de)
MA (1) MA30034B1 (de)
NO (1) NO20083089L (de)
PL (1) PL1963507T3 (de)
PT (1) PT1963507E (de)
RU (1) RU2008125041A (de)
TN (1) TNSN08252A1 (de)
WO (1) WO2007068704A1 (de)
ZA (1) ZA200805739B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4981381B2 (ja) * 2006-08-04 2012-07-18 株式会社ナリス化粧品 美白用皮膚外用剤
EP2105145A1 (de) * 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
JP5420669B2 (ja) * 2008-09-10 2014-02-19 エル、ベ、エム、アッシュ、ルシェルシュ 皮膚または毛髪の色素沈着の検討または調節に有用な方法、組成物で使用するための植物抽出物、および化粧的ケアの方法
EP2949752B1 (de) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Selbstfreisetzende rnai-verbindungen von reduzierter grösse
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
WO2011133876A2 (en) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
EP2814455B1 (de) 2012-02-13 2017-07-19 Unilever N.V. Hautaufhellende zusammensetzung
CN102925443A (zh) * 2012-11-01 2013-02-13 东北师范大学 靶向沉默MyoⅩ的序列制备及其载体的构建
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
CN105560635A (zh) * 2015-09-17 2016-05-11 张名静 一种治疗黑色棘皮病的中药
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência
JP2022541896A (ja) * 2019-07-18 2022-09-28 オリパス コーポレーション メラノフィリンアンチセンスオリゴヌクレオチド
WO2021020412A1 (ja) * 2019-07-30 2021-02-04 塩野義製薬株式会社 Murf1を標的とする核酸医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772607B1 (fr) 1997-12-19 2000-02-04 Oreal Utilisation de derives amides d'amino phenol comme agents depigmentants
GB9903216D0 (en) 1999-02-13 1999-04-07 Zylepsis Ltd Preservative compounds,compositions and methods of making and using the same
IL144850A0 (en) 1999-03-22 2002-06-30 Pfizer Resorcinol derivatives
HN2000000033A (es) 1999-03-22 2001-02-02 Pfizer Prod Inc Composicion de resorcinol
FR2804960B1 (fr) 2000-02-11 2005-06-24 Lvmh Rech Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
FR2864539B1 (fr) 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
EP1752536A4 (de) * 2004-05-11 2008-04-16 Alphagen Co Ltd Rna-störung verursachendes polynukleotid sowie verfahren zur regulation der genexpression unter verwendung davon

Also Published As

Publication number Publication date
HRP20100666T1 (hr) 2011-03-31
CA2632837A1 (fr) 2007-06-21
JP2009518022A (ja) 2009-05-07
IL191728A0 (en) 2011-08-01
EP1963507A1 (de) 2008-09-03
US7999096B2 (en) 2011-08-16
AU2006325359A1 (en) 2007-06-21
DK1963507T3 (da) 2011-01-03
ES2351996T3 (es) 2011-02-14
NO20083089L (no) 2008-07-10
TNSN08252A1 (en) 2009-10-30
KR20080079298A (ko) 2008-08-29
FR2894582B1 (fr) 2008-02-22
DE602006017586D1 (de) 2010-11-25
AU2006325359A2 (en) 2008-07-31
CN101326286A (zh) 2008-12-17
FR2894582A1 (fr) 2007-06-15
EP1963507B1 (de) 2010-10-13
PL1963507T3 (pl) 2011-04-29
ATE484585T1 (de) 2010-10-15
PT1963507E (pt) 2010-11-24
BRPI0619738A2 (pt) 2011-10-11
RU2008125041A (ru) 2010-01-20
WO2007068704A1 (fr) 2007-06-21
MA30034B1 (fr) 2008-12-01
US20090239934A1 (en) 2009-09-24
EP2264171A1 (de) 2010-12-22

Similar Documents

Publication Publication Date Title
ZA200805739B (en) Anti-myosin Va sirna and skin depigmentation
AU2008339215A8 (en) Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
EP2021507A4 (de) Zusammensetzungen und verfahren zur hemmung der pcsk9-genexpression
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
NZ546272A (en) The modulation of hyaluronan synthesis and degradation in the treatment of disease
WO2004058940A3 (en) Sirna-mediated gene silencing
ATE546526T1 (de) Hybrid-interferenz-rna
WO2004015062A3 (en) Methods and compositions relating to gene silencing
MX2012002272A (es) Dominios cataliticos de lisil oxidasa y loxl2.
MXPA05001355A (es) Formas nuevas adicionales de moleculas de arn de interferencia.
IL159756A0 (en) IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
ATE540118T1 (de) Antisense-verbindungen
EP1606304A4 (de) Genexpressionsregulierende nukleotidsequenzen sowie konstrukte und verfahren unter verwendung davon
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 siRNA 구조 및 그 용도
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
EP2023937A4 (de) Rnai-modulation von aha und ihre therapeutische verwendung
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
WO2006045591A3 (en) Method and constructs for delivering double stranded rna to pest organisms
WO2004061081A3 (en) Sirna compounds and methods for the downregulation of gene expression
WO2008001219A3 (en) Cancer therapy using bcl-xl-specific sina
ATE293688T1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide
DK1339853T3 (da) Isolerede luciferaser og deres anvendelse
WO2006047635A3 (en) Methods and compositions for seprase inactivation